A cute myocardial infarction is a leading cause of morbidity and mortality worldwide. 1 Myocardial ischemia/ reperfusion (MI/R) injury, sustained by ischemic myocardium after current reperfusion therapies (including thrombolysis, coronary angioplasty, and coronary bypass surgery), represents an important clinical problem with significant morbidity and mortality. 2 Novel pharmacological or molecular interventions mitigating reperfusion injury, adjunctive to current reperfusion therapies, are in great need.
specific roles of individual LXR subtypes in the regulation of cardiac physiology/pathology are at present unknown. The question of whether LXRα and LXRβ have discrete roles in cardiac physiology/pathology is particularly important because current strategies for LXR-targeted drugs are focused on development of tissue-and subtype-selective ligands.
In this study, we determined the regulatory role of 2 different LXR isoforms in the pathogenesis of MI/R-induced myocardial injury, using mice genetically depleted of LXRs (LXRα, LXRβ, or both) and in vivo intramyocardial adenovirus-mediated LXRα or LXRβ overexpression.
Methods
This investigation conformed to the National Institutes of Health Guidelines on the Use of Laboratory Animals and was approved by the Institute's Animal Ethics Committee. Experiments were performed on wild-type (WT) C57BL/6 and LXR-deficient (LXRα-, LXRβ-, or LXRα/β double-knockout) male mice. Pharmacological experiments used LXR endogenous agonist 22(R)-hydroxycholesterol [22(R)-HC] and synthetic agonist GW3965. 14, 15 In the acute MI/R protocol, reperfusion commenced for 24 hours after 30 minutes of ischemia. Mice were randomly assigned to the following groups: sham, vehicle, 22(R)-HC (20 mg/kg), or GW3965 (20 mg/kg) by intraperitoneal injection 15 minutes before reperfusion. To observe the long-term cardioprotective effect of LXRα/β dual agonists, mice were randomly assigned to one of the following groups: sham, vehicle, 22(R)-HC (20 mg/kg), or GW3965 (20 mg/kg) by intraperitoneal injection 15 minutes before reperfusion and daily after reperfusion for 4 weeks. Other experiments were designed for MI/R outcome determination in LXRα-, β-, and α/β double-deficiency mice and their WT littermates. Myocardial apoptosis was determined by terminal deoxynucleotidyl transferase dUTP nick end labeling technique and cardiac caspase-3 activity. Myocardial infarct size was determined by Evans blue-TTC (2,3,5-triphenyltetrazolium chloride) double staining methods. 16 In vivo cardiac function was determined by echocardiography. 17 Viable myocardium was assessed via micro-positron emission tomography/computed tomography scanning. Myocardial reactive oxygen species generation was measured by confocal microscopy via in situ dehydroetidium stain or lucigenin-enhanced chemiluminescence. Myocardial nitrative stress was assessed by nitrotyrosine content. In vivo knockdown of cardiac-specific LXRα or LXRβ expression was achieved by intramyocardial delivery of small interfering RNA. In vivo cardiac gene overexpression was achieved by adenoviral-encoded LXRα or LXRβ transfection. An expanded Methods appears in the Data Supplement.
Statistical Analysis
All values in the text and figures are presented as the mean±SEM of independent experiments from given n sizes. Statistical analysis was performed with Mann-Whitney test for 2-group comparisons. Statistical significance of multiple treatments was determined by Kruskal-Wallis tests followed by Dunn post hoc test. Probabilities of 0.05 or less were considered to be statistically significant (2 tailed).
Results

Both LXRα and LXRβ Are Expressed in Adult Heart Tissue, But LXRα Is Selectively Upregulated by Ischemia/Reperfusion
Both LXRα and LXRβ subtypes were detected in cardiac tissue, as demonstrated by both Western blot ( Figure 1A ) and real-time polymerase chain reaction ( Figure 1B ), albeit to lesser degree in comparison with those in the liver. More importantly, endogenous LXRα protein level significantly increased after reperfusion in the ischemic risk area, whereas LXRβ expression remained mostly unaffected ( Figure 1C and 1D). 
LXRα/β Dual Agonists Inhibit MI/R-Induced Myocardial Apoptosis, Infarct Size, and Cardiac Dysfunction
To determine whether post MI/R upregulation of LXRα mediates myocardial reperfusion injury or acts as a defensive prosurvival signal, mice were treated with vehicle, 22(R)-HC, or GW3965, and MI/R injury determinants were assessed. Treatment with LXR agonists had no significant effect on heart rate or mean arterial blood pressure ( Figure I in the Data Supplement). Compared with vehicle, administration of either 22(R)-HC or GW3965 significantly reduced the number of apoptotic nuclei and caspase-3 activity (Figure 2A ), decreased infarct size (from 40.2±1.0% in vehicle group to 15.7±1.2% [P=0.01] and 13.0±0.6% [P=0.001] in treated group, Figure 2B ), and improved echocardiographic measurements of left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (65.3±4.7% and 34.3±2.8% in the 22(R)-HC group, 60.7±2.6% and 29.2±2.4% in the GW3965 group, versus 39.5±2.1% and 20.7±1.6% in the vehicle group; LVEF: P=0.001, P=0.002 versus vehicle; left ventricular fractional shortening: P=0.002, P=0.04 versus vehicle, respectively; Figure 2C ). These data suggest that LXR activation plays an important cardioprotective role in acute MI/R injury.
To determine further the long-term cardioprotective effect of LXR agonists, mice received agonists 15 minutes before reperfusion and then daily after reperfusion for 4 weeks. Viable myocardial metabolism was assessed by fluorodeoxyglucose (18F) micro-positron emission tomography/computed tomography. Cardiac function was determined by echocardiography 4 weeks after reperfusion. MI/R markedly reduced mean myocardial standardized uptake values of fluorodeoxyglucose (18F). LXR agonists-treated mice manifested significantly increased fluorodeoxyglucose (18F) uptake compared with vehicle (2.6±0.2 in the 22(R)-HC group, 2.4±0.2 in the GW3965 group, versus 1.2±0.2 in the vehicle group, P=0.01 and P=0.04 respectively; Figure 3A and 3B). Furthermore, 22(R)-HC or GW3965 treatment significantly increased echocardiographic-measured LVEF compared with vehicle (53.7±4.7% in the 22(R)-HC-treated group or 52.7±5.6% in the GW3965-treated group, compared with 32.8±3.5% in the vehicle group, P=0.01 and P=0.02, respectively; Figure 3C ). 
LXRα/β Dual Agonists Inhibit the Endoplasmic Reticulum Stress-and Mitochondrial-Mediated Apoptosis Pathway
To determine the cellular mechanism by which LXR agonists reduces apoptosis and MI/R injury, the effects of LXR activation on caspase-12 (index of endoplasmic reticulum [ER] stress pathway), caspase-9 (mitochondrial pathway), and caspase-8 (death receptor pathway) activities were analyzed. As expected, all 3 caspases were activated after MI/R. However, administration of LXR agonists significantly inhibited caspase-12 and caspase-9 activity without altering caspase-8 activity ( Figure 4A ). Moreover, the cleaved caspase-12, CCAAT/-enhancer-binding protein homologous protein, cleaved caspase-9, and cytosolic cytochrome c levels were markedly increased in the ischemic/reperfused heart, and significantly inhibited by 22(R)-HC or GW3965 treatment (Figure 4B-4E). Taken together, these results suggest that LXR activation reduces postischemic myocardial apoptosis primarily by inhibiting the apoptotic pathways mediated by ER stress and mitochondria.
LXRα/β Dual Agonists Attenuate Oxidative/ Nitrative Stress in Ischemic/Reperfused Myocardium
To determine further the molecular mechanisms underlying the ER-and mitochondrial-mediated protective actions of LXR agonists, we investigated the effects of LXR activation on oxidative/nitrative stress in the ischemic/reperfused myocardium. Both 22(R)-HC and GW3965 attenuated MI/R-induced reactive oxygen species production ( Figure 5A and 5B). Furthermore, both LXR agonists inhibited the expression of gp 91phox subunit of the NADPH (nicotinamide adenine dinucleotide phosphate) oxidase ( Figure 5C ). Moreover, LXR agonists significantly reduced tissue nitrotyrosine content (a well-accepted footprint of in vivo nitrative stress, Figure 5D and 5E) and inhibited inducible nitric oxide synthase expression ( Figure 5F ). Collectively, these results demonstrate that LXR activation attenuated oxidative/nitrative stress after MI/R and subsequently inhibited the apoptotic pathways mediated by ER stress and mitochondria.
Cardioprotective Effects of LXRα/β Dual Agonist Are Impaired in Cardiac-Specific LXRα-Knockdown But Not LXRβ-Knockdown Mice
The aforementioned experimental results (MI/R upregulates LXRα but not LXRβ, and nonselective LXR agonists protect against MI/R injury) suggest that LXRα might be the cardioprotective LXR isotype. To obtain direct evidence supporting this notion, cardiac-specific gene silencing of either LXRα or LXRβ was performed before MI/R by in vivo intramyocardial small interfering RNA transfection ( Figure IIA in the Data Supplement). The cardioprotective effects of GW3965 were blunted when endogenous cardiac LXRα was knocked These results demonstrate that the cardioprotective effects of GW3965 may be primarily mediated by the LXRα-receptor subtype. Collectively, these results demonstrate that LXRα subtype activation attenuated oxidative/nitrative stress after MI/R and subsequently inhibited ER-and mitochondrialmediated apoptosis.
LXRα/β Double-Knockout and LXRα-Knockout, But Not LXRβ-Knockout, Increase MI/R Injury
To confirm further the role of the LXRα subtype in the MI/R injury, the effects of LXRα-, LXRβ-, and LXRα/β double-knockout on MI/R injury was investigated. The expression of LXRα and LXRβ subtypes in WT, LXRα-, LXRβ-, and LXRα/β double-knockout mice by Western blot and real-time polymerase chain reaction are shown in Figure 6A . Compared with WT controls, LXRα/β doubleknockout and LXRα-knockout mice exhibited increased apoptosis, infarct size, and cardiac dysfunction after acute MI/R ( Figure 6B and 6C) . Moreover, 4 weeks after reperfusion, LXRα/β double-knockout and LXRα-knockout mice exhibited decreased echocardiographic LVEF and fluorodeoxyglucose (18F) uptake of viable myocardium compared with WT controls ( Figure 6D ). In contrast, no significant difference was observed between LXRβ-knockout and WT mice ( Figure 6B-6D) . Mechanistically, knockout of LXRα/β and LXRα, but not LXRβ, exacerbated caspase-9 and caspase-12 activation and increased oxidative/nitrative stress after MI/R ( Figure 7A-7C ). Together, these results confirm that LXRα, not LXRβ, is the endogenous cardiac protective receptor against MI/R injury.
Cardioprotective Effects of LXRα/β Dual Agonist Are Lost in LXRα/β Double-Knockout and LXRα-Knockout But Not in LXRβ-Knockout Mice
To obtain more direct evidence supporting cardioprotective effects of LXRα subtype, we determined the effects of LXRαknockout, LXRβ-knockout, and LXRα/β double-knockout on 
Cardiac Overexpression of LXRα, But Not LXRβ, Suppresses MI/R Injury
Discussion
Our study provides new insights into understanding the discrete role of 2 different LXR subtypes in the heart. The novel contributions include the following: (1) Both LXRα and LXRβ subtypes were detected in adult cardiac tissue, but LXRα is selectively upregulated by ischemia/ reperfusion; (2) LXRα/β dual agonists inhibited MI/Rinduced infarct size and cardiac dysfunction via inhibition of oxidative/nitrative stress, and subsequently reducing the apoptotic pathways mediated by ER stress and mitochondria; (3) The cardioprotective effects of LXRα/β dual agonist were impaired in the setting of cardiac-specific gene silencing via in vivo intramyocardial transfection of small interfering RNA of LXRα, but not LXRβ, subtype; (4) LXRα/β double-knockout and LXRα-knockout, but not LXRβ-knockout, increased MI/R injury, exacerbated MI/R-induced oxidative/nitrative stress, and ER stress and mitochondrial dysfunction; (5) LXRα/β double-knockout and LXRα-knockout, but not LXRβ-knockout, completely blocked the cardioprotective effects of LXR agonists; and (6) Cardiac LXRα, not LXRβ, overexpression via adenoviral transfection suppressed MI/R injury. In summation, we present the first direct evidence that the LXRα, but not LXRβ, subtype is a novel endogenous cardiac protective receptor against MI/R injury. LXRs, orphan nuclear hormone receptors originally cloned in liver tissue, 18 function as cholesterol sensors with well-recognized function in regulating cholesterol homeostasis. 7 Two different but highly homologous LXR isoforms, LXRα (NR1H3) and LXRβ (NR1H2), have been discovered separately. The human LXRα gene is located on chromosome 11p11.2, whereas the human LXRβ gene is located on chromosome 19q13.3. LXRα expression predominates in metabolically active tissues such as the liver, kidney, adipose, and intestines, whereas LXRβ is more ubiquitously expressed with particularly high levels in the developing brain, 7,19 suggesting differential physiological function regulation for these 2 receptors. Although LXRα and LXRβ presence in the cardiovascular system had been identified, [8] [9] [10] [11] [12] [13] little information is available regarding their individual roles in the myocardium. To our knowledge, this study is the first to investigate the specific roles of 2 individual LXR subtypes in the cardiac physiology/pathology. The results of our study contribute to the growing body of data emphasizing that the distinctively isoform-specific functions of LXR are mediated by 2 different receptors, by demonstrating that LXRα, a subtype with previously unappreciated cardiovascular significance, but not LXRβ, a subtype known to be ubiquitously expressed (including heart), is a novel endogenous cardiac protective receptor against MI/R injury. This conclusion is supported by the following novel evidence. First, the expression of LXRα (but not LXRβ) was significantly increased in the heart subjected to MI/R. Second, MI/R injury was significantly increased in LXRα/β doubleknockout and LXRα-knockout, but not in LXRβ-knockout mice. Third, genetic ablation (knockout or cardiac-specific knockdown) of LXRα, but not LXRβ, blocked the cardioprotective effect of LXRα/β dual agonists. Fourth, cardiacspecific LXRα, but not LXRβ, overexpression suppressed MI/R injury. Our current observations enrich our understanding of the different biological functions of LXRα and .99, ‡P=0.04 vs WT]) and caspase-3 activation (n=5-6; *P=0.02, †P>0.99, ‡P=0.03 vs WT). C, MI/R injury was assessed by myocardial infarction size determined by Evans blue/TTC (2,3,5-triphenyltetrazolium chloride) double-staining (n=6; *P=0.007, †P>0.99, ‡P=0.03 vs WT), and left ventricular dysfunction determined by echocardiography (n=6; *P=0.03, †P>0.99, ‡P=0.04 vs WT). D, Cardiac function was determined by left ventricular viable myocardium assessed via fluorodeoxyglucose (18F) ( 18 F-FDG) uptake (mean standardized uptake values [SUV]) by micro-positron emission tomography/computed tomography (n=5-6; *P=0.04, †P>0.99, ‡P=0.01 vs WT), and left ventricular performance determined by echocardiography (n=6; *P=0.04, †P>0.99, ‡P=0.02 vs WT). AAR indicates area at risk; ECHO, echocardiography; and LVEF, left ventricular ejection fraction.
LXRβ in different tissues. The LXRα subtype is the isoform responsible for hepatic lipogenesis, 20 with a dominant role in limiting atherosclerosis in vivo. 9 The LXRβ subtype regulates lipogenesis and cholesterol efflux in skeletal muscle, 21 with antithrombotic effects in human platelets. 22 Such data concerning tissue-and isoform-specific effects of LXRs are of practical interest in the development of tissueor isoform-specific LXR pharmacological modulators for treating various pathologies. 23 To provide mechanistic insight into how LXR activation protected heart against MI/R injury, we investigated the effect of LXR activation on the apoptosis pathway, a significant contributor to myocardial cell death after ischemia/reperfusion injury. Our study demonstrated that during MI/R, all 3 apoptosis pathways (the extrinsic, intrinsic, and ER stress-specific apoptotic pathways) were activated, as shown by the activation of different caspase markers (caspase-8, caspase-9, and caspase-12, respectively). LXR activation attenuated the activation of markers of ER stress (cleaved caspase-12 and CCAAT/-enhancer-binding protein homologous protein) and mitochondrial stress (cleaved caspase-9 and cytochrome c release) without altering cleaved caspase-8 protein levels (the extrinsic apoptotic marker) and its activity. To define the role of the different LXR isoforms in the regulation of cardiomyocyte apoptosis, LXRαknockout, LXRβ-knockout, and LXRα/β double-knockout mice were subject to MI/R. We observed that, compared with WT mice, ER stress-and mitochondrial-mediated apoptosis was exacerbated after MI/R in LXRα/β doubleknockout and LXRα-knockout, but not LXRβ-knockout mice. Furthermore, the ER-and mitochondrial-protective effects of LXR agonist were lost in the setting of genetic ablation of LXRα, but not LXRβ subtype. Thus, LXRα but not LXRβ inhibited the apoptotic pathways mediated by ER stress and mitochondria. Because oxidative/nitrative stress is causatively related to ER stress and mitochondrial dysfunction, we further determined the role of the different LXR isoforms in the regulation of oxidative/nitrative stress. We demonstrated that activation of LXRα, but not LXRβ, significantly decreased myocardial NADPH oxidase expression, attenuated superoxide generation, and reduced both inducible nitric oxide synthase expression and tissue nitrotyrosine content in ischemic/reperfused myocardium. Taken together, our results demonstrated LXRα subtype protected against MI/R injury via mechanisms inhibiting oxidative/nitrative stresses, subsequently reducing ER-and mitochondrial-mediated apoptosis.
The involvement of LXR in regulating the apoptotic process has been reported in several cell and tissue types. Interestingly, LXR activation was shown to be antiapoptotic in several cell types, and proapoptotic in others. For example, LXR activation inhibited apoptosis in endothelial cells, 24 intestine, 25 and lung tissue 26 but facilitated apoptosis in tumor cells, such as breast, colorectal, and prostate carcinomas. [27] [28] [29] Thus, the role of LXR in inhibiting or promoting apoptosis may be dependent on cell and tissue type.
Heretofore, several members of the nuclear hormone receptor superfamily have reputed involvement in MI/R injury pathophysiology. Peroxisome proliferator-activated receptors (PPAR-α [NR1C1], -β [NR1C2], and -γ [NR1C3]), 3 estrogen receptor (NR3A), 30 and androgen receptor (NR3C4) 31 have been proposed as the endogenous protective receptors against myocardial apoptosis and MI/R injury, while activation of nuclear receptor farnesoid-X-receptor (NR1H4) 6 and Figure 7 . Liver-X-receptor (LXR)α/β double-knockout (KO) and LXRα-KO mice exacerbated oxidative/nitrative stresses in ischemic/reperfused myocardium. A, Caspase-9 and caspase-12 activity was measured by fluorometric assay (n=5-6; caspase-12: *P=0.03, ‡P>0.99, | |P=0.007 vs wild type [WT]; caspase-9: †P=0.008, §P>0.99, #P=0.03 vs WT). B, Myocardial oxidative stress was measured using confocal microscope with in situ dihydroethidium stain (n=5-6, bar=25 μm). Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity was determined by lucigenin-enhanced chemiluminescence (n=5-6; *P=0.02, †P>0.99, ‡P=0.005 vs WT). NADPH oxidase gp 91phox gene expression was determined by real-time polymerase chain reaction (PCR; n=5-6; *P=0.04, †P=0.61, ‡P=0.02 vs WT). Results were normalized against GAPDH and converted to fold induction relative to WT mice. C, Nitrative stress was assessed by nitrotyrosine levels determined by immunohistochemistry (n=5-6, bar=25 μm). Myocardial nitrotyrosine content was determined by ELISA analysis (n=5-6; *P=0.01, †P=0.43, ‡P=0.01 vs WT). Inducible nitric oxide synthase gene expression was determined by real-time PCR (n=5-6; *P=0.008, †P>0.99, ‡P=0.02 vs WT). Results were normalized against GAPDH and converted to fold induction relative to WT mice. MI/R indicates myocardial ischemia/reperfusion; and RLU, relative light units. Nur77 (NR4A1) 5 exacerbates myocardial apoptosis and MI/R injury. Our study adds novel evidence that LXRα (NR1H3) acts as an endogenous protective factor against MI/R injury. Given the distinct regulatory roles of these nuclear receptors in myocardial apoptosis and MI/R injury, it is conceivable that potential regulatory cross talk among them might maintain the delicate homeostatic balance between cellular death and survival in the heart. Of particular interest is a human macrophage study demonstrating PPARγ activation directly increased LXRα expression via PPAR binding to an LXRα promoter site. 32 In a study investigating adipocytes, activated LXRα promoted PPARγ gene expression by directly binding the LXR response element motif in the PPARγ promoter in a positive-feedback loop, 33 such that these 2 nuclear hormone receptors reinforced each other's expression. Characterization of the molecular cross talk between these nuclear receptor pathways is requisite for better design of novel therapeutics ameliorating MI/R injury.
Conclusions
In summary, our study provides the first evidence that LXRα, a LXR subtype traditionally viewed as a metabolic regulatory factor, has much stronger cardiac phenotype than ubiquitously expressed LXR subtype, LXRβ. LXRα (but not LXRβ) subtype is a powerful cardiac protection receptor against MI/R injury, via mechanisms (at least in part) inhibiting oxidative/ nitrative stresses, and subsequently reducing ER-and mitochondrial-mediated apoptosis. LXRα subtype, therefore, represents a potentially attractive molecular target for the treatment of ischemic heart disease. 
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